$CLPT | ClearPoint Neuro is not just on my radar, it's a position I consciously hold in my portfolio. The reason is clear: the company offers a real solution to a problem in neurosurgery that no one has been able to fundamentally address for a long time. ClearPoint's system provides real-time MRI guidance during surgery, making operations less invasive, safer, and more predictable. The fact that this FDA-approved platform is actively used in more than 100 centers in the US shows that it's no longer just a "vision," but a technology working in the field.
The important point here is that traditional neurosurgery still relies heavily on static stereotactic imaging. That is, operations are managed using images taken before surgery. This method has been used for years, but it has serious limitations in terms of accuracy, speed, and safety. In an area like the brain, which requires millimeter precision, working without live feedback naturally increases the margin of error. This is where ClearPoint makes a difference: it offers the surgeon real-time guidance with instant MRI images during the operation. This also means shorter operation times, fewer complications, and better patient outcomes.
What excites me most about this company is that the technology isn't limited to its current use cases. The ClearPoint platform offers an infrastructure that can extend to areas such as deep brain stimulation (DBS), laser ablation, gene therapies, biotechnological drug delivery, and even EEG. So, we're not talking about a single product here, but a surgical platform that can expand to different indications over time. This sets the company apart from a classic medtech manufacturer. The scalability of its business model also supports this thesis. The structure, consisting of software, hardware, disposable accessories, and licensing revenue, clearly reminds me of $TMDX | TransMedics' OCS platform. There, the real value was the platform itself and the continuous revenue cycle built around it, rather than the device. ClearPoint has the potential to follow a similar path. Once installed, each procedure represents recurring revenue for the company.
On the competitive side, the most frequently mentioned player is $ROSA | Robotic Stereotactic Assistance. However, the fact that ROSA still operates based on classic stereotactic imaging further clarifies ClearPoint's MRI-based advantage. Here, the technological difference is not cosmetic; it is changing the fundamental way surgery is performed. The company's strategic partnerships should also not be overlooked. The positioning of strong biotechnology players like PTC Therapeutics as investors and partners suggests that ClearPoint could become a critical platform not only for surgical guidance but also for targeted drug delivery in the future. Its use in over 4,000 procedures to date demonstrates that this technology has proven itself in practice, not just in theory. Three main areas are particularly critical for me: precise delivery of biological drugs to the correct point, DBS applications, and laser therapies.
The essence of my investment thesis is this: ClearPoint's real-time MRI technology will raise the standards in neurosurgery. The company is active in 100+ centers today and could become the preferred delivery platform for biotechnology companies tomorrow. If this growth trajectory is maintained and clinical adoption accelerates, it could become a success, just like $ISRG | Like Intuitive Surgical's impact on robotic surgery, ClearPoint could become a benchmark in its niche. Of course, this is a very high-risk investment. The company is still in its early stages, and there are uncertainties. My only advantage here is that I got involved in this story early. However, I believe that the value the technology will create as it gains clinical acceptance has the potential to more than offset today's risks. $CLPT is one of the rare companies that could write the standards for the future of neurosurgery.
The information, comments and recommendations contained herein are not within the scope of investment consultancy. Investment consultancy services are provided within the framework of the investment consultancy agreement to be signed between brokerage firms, portfolio management companies, banks that do not accept deposits and customers. The comments in this article are only my personal comments and these comments may not be appropriate for your financial situation and risk return. For this reason, investments should not be made based on the information and comments in my articles.
